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Abstract
Background: Results from genetic epidemiological studies suggest that raised serum homocysteine is a cause of ischaemic
heart disease, but the results of randomised trials suggest otherwise. We aimed to update meta-analyses on each type of
study using the latest published data and test a hypothesis based on antiplatelet therapy use in the trials to explain the
discrepancy.
Methods and Findings: Meta-analyses of ischaemic heart disease using (i) 75 studies in which the prevalence of a mutation
(C>T) in the MTHFR gene (which increases homocysteine) was determined in cases (22,068) and controls (23,618), and (ii)1 4
randomised trials (39,597 participants) of homocysteine lowering and ischaemic heart disease events. The summary
estimates from the two analyses were compared. Meta-analysis of the MTHFR studies showed a statistically significantly
increased risk of ischaemic heart disease in TT compared with CC homozygotes; odds ratio 1.16 (1.04 to 1.29) for a 1.9 mmol/
L homocysteine difference (TT minus CC). Meta-analysis of randomised trials showed no significant reduction in IHD risk
from folic acid; relative risk 1.00 (0.93 to 1.08), despite a reduction in homocysteine of 3.3 mmol/L. There was a statistically
significant difference in risk reduction between the 5 trials with the lowest prevalence of antiplatelet therapy (60% on
average, usually aspirin), RR 0.93 (0.84 to 1.05) and the 5 trials with the highest prevalence (91% on average), RR 1.09 (1.00 to
1.19), p=0.037 for the difference.
Conclusion: Discordant results from MTHFR studies and randomised trials could be explained by aspirin reducing or
negating the anti-platelet effect of lowering homocysteine. On this basis, folic acid would have a role in the primary
prevention of ischaemic heart disease, when aspirin is not taken routinely, but not in secondary prevention, when it is
routine.
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Introduction
There is uncertainty over whether raised serum homocysteine
concentrations cause ischaemic heart disease. Two types of study
provide evidence: (i) case control studies of the prevalence of the
methylenetetrahydrofolate reductase (MTHFR) gene polymorphism (a
common genetic variant that leads to moderate increases in serum
homocysteine levels) among people with and without ischaemic heart
disease [1,2] and (ii) randomised trials of B vitamins, which lower
serum homocysteine, in the prevention of ischaemic heart disease
e v e n t s . [ 3 ]T h er a n d o m i s e dt r i a l ss h o u l db eav a l i dt e s to ft h eh y p o t h e s i s
that homocysteine causes ischaemic heart disease, provided risk can be
reversed within a few years – the duration of most of the trials.
The MTHFR studies, themselves, provide evidence of causality
comparable to that obtained from the randomised controlled trials, in
that the serum homocysteine differences in people with and without
the polymorphism occur as a result of a randomly allocated genetic
mutation and the two groups would not be expected to differ in other
respects. While it is theoretically possible that B vitamins influence
ischaemic heart disease risk through means other than homocysteine,
none have been shown. Meta-analyses of MTHFR studies show a
statistically significantly higher risk of ischaemic heart disease in TT
homozygotes (the variant with higher homocysteine)[2–4] than in CC
homozygotes (the variant with lower homocysteine), but meta-
analyses of randomised trials of homocysteine lowering have
indicated that folic acid, which lowers homocysteine does not reduce
the risk of ischaemic heart disease.[3,5]
Additional MTHFR studies and randomised trials have been
published since the last meta-analyses. [3–5] We here update the
meta-analyses to provide a quantitative comparison between the
two types of study and investigate a possible explanation (based on
concomitant use of antiplatelet therapy in the trials) that could
explain the discrepant results.
Methods
We updated our previous meta-analyses [2] of (i) MTHFR
studies that reported the prevalence of the TT, CT and CC
genotypes in ischaemic heart disease cases and controls and (ii)
MTHFR studies that reported serum or plasma homocysteine
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cardiovascular disease. We adopted our previous search strategy
[2] but included only studies on ischaemic heart disease and
extended the inclusion of studies to those published up to July
2010. The search identified an additional 64 MTHFR studies (114
in total) since the previous meta-analyses (Figure S1). We updated
our previous meta-analysis of randomised placebo-controlled trials
of serum homocysteine reduction and ischaemic heart disease
events [3] including trials published up to July 2010. The search
identified an additional 7 trials (14 in total) since the previous
meta-analysis. Data were extracted independently by two
investigators and the data-sets cross-checked.
In the MTHFR studies patients with ischaemic heart disease had
myocardial infarction or angiographically confirmed coronary
artery occlusion (.50% of the luminal diameter). The control
groupswere fromthegeneral population orpatientswhounderwent
coronary angiography but had normal coronary arteries. Patients
with mild angiographic coronary artery disease (,50% occlusion of
the luminal diameter) who were, in some studies, classified as
control subjects were excluded from the meta-analysis. We
restricted our analysis to studies in which MTHFR polymorphisms
(TT, CT or CC) were confirmed by DNA testing. The studies
therefore compared the risk of ischaemic heart disease in people
with higher (TT) and lower (CC) homocysteine levels, the two
groups determined at random through natural allele assortment.
In each MTHFR study we determined the odds ratio for
ischaemic heart disease in TT versus CC homozygotes, and
separately in CT versus CC, in cases and controls. We used a
random effects model to derive summary odds ratios from
combinations of studies to take account of heterogeneity across
studies. We performed a meta-regression analysis of odds ratio
(TT versus CC) against the homocysteine difference between TT
and CC in studies where both were reported. From studies that
reported serum homocysteine according to genotype in individuals
without a history of cardiovascular disease, we calculated summary
mean serum homocysteine differences (TT minus CC and CT
minus CC), weighting studies by the inverse of the variance.
In the randomised trials we calculated the relative risk of
ischaemic heart disease (death or non-fatal myocardial infarction)
in each trial and used a random effects model to derive a summary
relative risk estimate from combinations of trials. A pre-specified
analysis was performed on the results of the trials in which the use of
antiplatelet therapy was reported, separating them in to the half with
the lowest and the half with the highest prevalence of antiplatelet
therapy. STATA software (version 10) was used for all analyses.
Results
Studies of MTHFR mutation
The database search identified 75 MTHFR studies comparing
the prevalence of TT with CC homozygotes in cases with
ischaemic heart disease (22, 068 in total) and controls (23,618).
Figure 1 shows the odds ratios for TT versus CC, with the studies
ranked in order of increasing effect. The summary odds ratio was
1.16 (95% confidence interval 1.04 to 1.29; p=0.006), so risk was
16% higher in TT than CC. The summary estimate for CT versus
CC was 1.04 (0.99 to 1.10). There was significant heterogeneity
between studies (I
2=49.9%, p,0.001). Figure S2 is a plot of the
standard error of the log odds ratio (TT versus CC) against the
odds ratio for each MTHFR study (a funnel plot). The symmetry
of the plot provides evidence against publication bias. Citations of
the relevant published articles are given in Table S1.
Figure 2 shows a plot of the odds ratio of ischaemic heart disease
against the serum homocysteine difference between TT and CC
among control subjects in the 14 studies that reported these data.
The plot ranks the studies by observed serum homocysteine
difference and stratifies them into three groups according to serum
homocysteine difference. The studies with similar homocysteine
concentrations in the TT and CC groups showed no increased risk
of ischaemic heart disease, whereas those with higher homocys-
teine in the TT group tended to have an increased risk. The odds
ratio increased by 1.13 (1.00 to 1.27) for a 1 mmol/L increase in
serum homocysteine (p=0.013).
Table S2 lists 53 studies (36 167 participants), including the 14
from figure 2, which reported serum homocysteine but not risk of
ischaemic heart disease according to MTHFR genotype in people
without a history of cardiovascular disease. Citations of the relevant
published articles are given in Table S3. The average serum
homocysteine difference for TT minus CC was 1.9 mmol/L (1.5 to
2.2). Thus the expected dose-response relationship for TT versus CC
is a relative risk of 1.16 for a 1.9 mmol/L serum homocysteine
increase - lower than our previous published estimate of 2.7 mmol/L,
[2] which included estimates from people with cardiovascular disease.
Randomised Trials
Thedatabase searchidentified 14 randomised placebo-controlled
trials of B vitamins on serum homocysteine reduction (Table 1),
including 39,597 participants recording 3233 ischaemic heart
disease events (cardiac death or non-fatal myocardial infarction).
Citations for the relevant published trials are given in Table S4.
Figure 3 shows a meta-analysis plot of the 14 trials. The
summary relative risk was 1.00 (0.93 to 1.08) for a mean serum
homocysteine reduction of 3.3 mmol/L. There was no significant
heterogeneity between the trial results (I
2=11.1%, p=0.421).
Figure 4 shows a meta-analysis plot of the 10 trials that reported the
use of antiplatelet therapy, separated in to the 5 with the lowest
prevalence of antiplatelet therapy (60% on average, usually aspirin)
and the 5 with the highest prevalence (91% on average). The summary
relative risks of ischaemic heart disease events were 0.94 (0.84 to 1.05)
and 1.09 (1.00 to 1.19) respectively (p=0.037 for the difference
between the two estimates), suggesting an antiplatelet therapy-
homocysteine interaction (see Discussion). A meta-regression, based
on the individual trials, of the prevalence of anti-platelet therapy on
relative risk of ischaemic heart disease gave a similar result (p=0.056).
Comparing the results from the two types of study
The meta-analysis of randomised trials showed that folic acid did not
reduce the risk of ischaemic heart disease even though, on average,
serum homocysteine was reduced by 3.3 mmol/L (relative risk (1.00
(0.93 to 1.08)). The meta-analysis of the MTHFR studies shows a
statistically significant higher risk of IHD (odds ratio 1.16 (1.04 to 1.29)
in TT than CC individuals for a 1.9 mmol/L homocysteine difference.
This is equivalent to an odds ratio of 0.79 (0.67 to 0.93) for the same
3.3 mmol/L homocysteine difference observed in the trials. The
summary result from the trials indicates that a reduction in risk of more
than 7% (lower 95% confidence interval) is unlikely. The summary
result from the MTHFR studies indicates that a reduction in risk of less
than 7% (upper 95% confidence interval), for the same homocysteine
difference, is unlikely. The results of the randomised trials and the
MTHFR studies are thus discordant.
Figure 1. Meta-analysis of MTHFR studies and ischaemic heart disease: odds ratios (95% confidence intervals) for TT versus CC
homozygotes.
doi:10.1371/journal.pone.0016473.g001
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The discordant results from the randomised trials and MTHFR
studies needs to be explained. A possible explanation is that
lowering homocysteine may not add to the effect of aspirin and
possibly other antiplatelet drugs in preventing ischaemic heart
disease. Aspirin irreversibly blocks the formation of thromboxane
A2 in platelets, producing an inhibitory effect on platelet activation,
platelet aggregation and preventing thrombosis. [6] Homocysteine
increases platelet activation, thromboxane production, and platelet
Table 1. Characteristics of randomised trials of serum homocysteine lowering on ischaemic heart disease events.
Study (country)*
Number of





Folic acid B12 B6
CHAOS - 2 (UK)
z1 1882 IHD 5.0 - - NR 20
WAFACS (USA)
z2 5442 CVD 2.5 1.0 50 51 88
VISP (USA)
z3 3680 Stroke 2.5 0.4 25 NR 20
ASFAST (Australia)
z4 315 Renal 15.0 - - 22 43
Goes (Netherlands)
z5 593 IHD 0.5 - - NR 42
Swiss Heart (Switzerland)
z6 553 IHD 1.0 0.4 10 94 6
WENBIT (Norway)
z7 3090 IHD 0.8 0.4 40 90 38
HOPE-2 (Canada)
z8 5522 CVD 2.5 1.0 5 80 60
NORVIT (Norway)
z9 3749 IHD 0.8 0.4 40 90 36
SEARCH (UK)
z10,z15 12064 IHD 2.0 1.0 - 91 84
Lange* (Germany)
z11 636 IHD 1.2 0.6 48 100 6
DIVINe (Canada)
z12 238 Diabetic Renal 2.5 1.0 25 62 32
HOST (USA)
z13 2056 Renal 40.0 2.0 100 40 38
Righetti* (Italy)
z14 88 Renal 5.0 0.5 250 NR 29
*first author if study not named.
{aspirin and/or another antiplatelet drug.
IHD – ischaemic heart disease, CVD – Cardiovascular Disease.
NR – not reported.
doi:10.1371/journal.pone.0016473.t001
Figure 2. Dose-response relationship between odds ratio of ischaemic heart disease and difference in serum homocysteine
concentrations between TT and CC homozygotes from meta-analysis of MTHFR studies.
doi:10.1371/journal.pone.0016473.g002
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human studies and may explain the pathological effects of
homocysteine in both arterial and venous disease. [7] A Medline
literature search identified 22 studies on the effect of homocysteine
on platelet function [8–29]. Seventeen studies showed a statistically
significant (p,0.05) effect of homocysteine on increasing pro-
thrombotc platelet function (increased platelet activation,[8–16]
thromboxane production [17–20] orplatelet aggregation[21–22]), 4
were inconclusive [25–28] and 1 showed an effect in the opposite
direction.[29] The evidence that homocysteine increases prothrom-
botic platelet function is thus persuasive. In one of these studies on
patients with homocystinuria, urinary excretion of thromboxane B2
(a metabolite of thromboxane A2) was about 5-fold higher in
patients compared with healthy controls; an effect that was reversed
on giving aspirin (50 mg/day). [18]
Given that homocysteine exerts a thrombotic effect through its
action on platelet function, concomitant treatment with aspirin (or
possibly other ant-platelet drugs) could reduce or negate the
antiplatelet effect of lowering homocysteine in the trials. All but 4
of the randomised trials were conducted in patients with prior
vascular disease, most of whom took antiplatelet drugs (usually
aspirin) during the trial. Aspirin use prior to a diagnosis of
ischaemic heart disease in the MTHFR studies was not reported,
but this is likely to have been rare in individuals without ischaemic
heart disease, because antiplatelet drugs were not routinely used in
the absence of a specific indication (such as aspirin for arthritis). A
negative interaction between antiplatelet therapy and homocyste-
ine would not, therefore, apply in the MTHFR studies.
The hypothesis that aspirin reduces or negates the anti-platelet
effect of lowering homocysteine, receives support from the
observation that there was a statistically significant difference in
risk reduction between the 5 trials with the lowest prevalence of
concomitant antiplatelet therapy and the 5 trials with highest
prevalence (p=0.037). A limitation of this analysis is that it could
only be undertaken on 10 of the 14 trials and it is possible that the
division of trials in to the two groups could have given rise to a
chance finding. However the hypothesis was proposed before the
analysis was performed (ie. it was not data-derived) and it would
explain the discordance between the results of the randomised
trials and the MTHFR studies. Another limitation is that data
were not available to explore the possibility, albeit unlikely, that
individuals who took antiplatelet therapy in the trials, had an
underlying medical condition that negated a preventive effect of
homocysteine lowering on ischaemic heart disease.
The 5 trials with the lowest prevalence of antiplatelet therapy
yielded a relativerisk of ischaemic heart diseaseof 0.94. If theproposed
hypothesis is correct, this relative risk estimate would arise only from
the 40% of trial participants who were not taking concomitant aspirin,
so the expected relative risk (RR) if none were taking aspirin would be
0.85 (0.46RR +0.661=0.94); an estimated 15% reduction in risk of
ischaemic heart disease. The fact that most of the trials included
patients with pre-existing cardiovascular disease leaves open the
possibility that folic acid has a useful role in the primary prevention of
ischaemic heart disease, where aspirin is generally not used, but not in
secondary prevention, where it is routine.
Weighing the evidence
The evidence from the MTHFR studies indicates an association
that is unlikely to be due to chance (p=0.006). The studies exclude
confounding, as generally understood, because the raised homo-
cysteine concentrations occur as a result of a genetic mutation
randomly distributed across the population; people with and
without the mutation would not in expectation differ in other
cardiovascular risk factors and direct observation has shown that
they do not.[3] Genetic confounding is theoretically possible if there
were a gene linked to the MTHFR polymorphism that also
increases serum homocysteine and IHD risk. No such gene linkage
has been identified and the probability of it accounting for the
positiveassociationslinkingtheMTHFR variant,homocysteine and
ischaemic heart disease is, as previously described, low.[3,30] The
studies are, in effect, natural randomised experiments, capable of
testing whether moderately raised homocysteine causes ischaemic
heart disease. The result supports a causal relationship. A previous
meta-analysis of MTHFR studies and stroke found a statistically
significant effect (odds ratio 1.26 (1.14 to 1.40) for TT versus CC)
and the authors concluded that the association was causal. [30]
The finding ofsignificant heterogeneity (greatervariation between
study results than would be expected through chance) in the
Figure 3. Meta-analysis of randomised trials of serum homocysteine reduction on ischaemic heart disease events (cardiac death
and non-fatal myocardial infarction). * first author given if study not named.
doi:10.1371/journal.pone.0016473.g003
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on serum homocysteine levels depends on environmental factors,
notably dietary folate. So, if dietary folate is high, the expression of
the TT phenotype is reduced, homocysteine is less elevated and
therefore the risk of ischaemic heart disease is less increased.
[1,3,30,]. There were few direct measures of dietary folate intake in
the studies available, so stratified analyses according to folate intake
were not possible. The closest one can get to explaining the
heterogeneity is the meta-regression illustrated in Figure 2, and this
indicatesthatstudies inpopulationswith similarhomocysteine inTT
and CC groups tended to find no difference in ischaemic heart
diseaserisk,whereasstudiesinpopulationswithhigherhomocysteine
in TT than CC groups tended to find higher risk (p=0.013).
Howeverthelimitationsinourabilitytoexplaintheheterogeneitydo
not invalidate the result that, in general, TT individuals have a
higher ischaemic heart disease risk than CC individuals.
Publication bias (the preferential publication of small positive
studies over small negative ones) is likely to influence the meta-
analysis but not to an extent that would explain the overall positive
result. From Figure 1, 12 out of the 75 MTHFR studies had
statistically significantly positive results but only two were
statistically significantly negative. If there were no true association
between the MTHFR polymorphism and ischaemic heart disease
risk then the probability of a statistically significant result arising by
chance (at the 5% level) would be 1 in 20 or 1 in 40 for positive
results and 1 in 40 for negative results. From the 75 studies, about
two statistically significantly positive results and two statistically
significantly negative results would be expected by chance. The
two statistically significant negative results are therefore expected
but the 12 statistically significantly positive results are not (p=0.01
for the difference between the two expected and 12 observed). For
publication bias to have generated the positive overall result,
therefore, these 12 studies would have to have come from a pool of
480 (12640) studies, with 405 (480-75) of them remaining
unpublished. It is unlikely that so large a number of researchers
would fail to publish their studies, effectively excluding publication
bias as a plausible explanation for the positive result.
Inassessingwhetherhomocysteinecausesischaemicheartdisease,
the effect of lowering serum homocysteine in reducing cardiovas-
cular disease risk in patients with homocystinuria is relevant.
Individuals with homozygous homocystinuria have homocysteine
concentrations about 5 times greater than average and a 1 in 2
chance of a vascular disease event before age 30. [31] Treatment to
lower serum homocysteine reduced risk by about 90% (compared
with the risk in non-randomised untreated controls), an effect so
large that selection bias is unlikely to account for the result. [32,33]
This supports the causal conclusion from the MTHFR studies.
Although the meta-analysis of trials on ischaemic heart disease
showed no protective effect of homocysteine reduction, a meta-
analysis of trials of serum homocysteine reduction on stroke
prevention by Wang and colleagues showed that folic acid reduced
the riskofstrokeby18%(relativerisk0.82(0.68–1.00)).[34]Itwould
be surprising to observe a preventive effect on stroke but not on
ischaemic heart disease. Four of the eight trials in Wang’s meta-
Figure 4. Meta-analysis of randomised trials of serum homocysteine reduction on ischaemic heart disease events (cardiac death
and non-fatal myocardial infarction) according to use of antiplatelet therapy.
doi:10.1371/journal.pone.0016473.g004
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and would not tend to be on antiplatelet therapy. This may explain
the observed preventive effect of folic acid in the stroke trial meta-
analysis and not in the ischaemic heart disease meta-analysis.
In conclusion, the negative trial evidence on ischaemic heart
disease should not trump the positive evidence from the MTHFR
studies and hence mistakenly lead to a conclusion that there is no
role for folic acid in preventing ischaemic heart disease. There is
evidence that folic acid has a modest but useful role in the primary
prevention of ischaemic heart disease and concomitant use of
aspirin, and possibly other antiplatelet therapy, is an explanation
for why this is not evident in the results of the randomised trials.
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